Lipids and risk assessment

Cardiology in Review

Volumn 9, Issue 6, 2001, Pages 348-358

  Linde, Randy ^a   Linde, Bonnie ^b  

^a PALO ALTO MEDICAL FOUNDATION   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein; Atherosclerosis; Cardiac risk; Cholesterol; Lipoprotein

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LIPID; LIPOPROTEIN A;

ADULT; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; EVALUATION; FAMILY HISTORY; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY TEST; LIPID BLOOD LEVEL; MALE; MEASUREMENT; REVIEW; RISK ASSESSMENT; X RAY ANALYSIS;

EID: 0035187111     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045415-200111000-00011     Document Type: Review

References (51)

1. 2 levels and decreased hepatic lipase activity
2. Atherosclerotic disease in marked hyperalphalipoproteinemia: Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase
3. Genetic determinants of high-density lipoprotein levels
4. High-density lipoproteins and arteriosclerosis: Role of cholesterol efflux and reverse cholesterol transport
5. Detection and quantitation of LDL subfractions
6. Quantification of cholesterol in all lipoprotein classes by the VAP-II method
7. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy
8. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study
9. Proliferation of human smooth muscle cells promoted by lipoprotein (a)
10. Lipoprotein (a) inhibits the generation of transforming growth factor β: An endogenous inhibitor of smooth muscle cell migration
11. Lipoprotein (a) and coronary heart disease. Meta-analysis of prospective studies
12. Lipoprotein (a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease
13. Modulation of lipoprotein (a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol
14. Proteoglycans contribution to association of Lp(a) and LDL with smooth muscle cell extracellular matrix
15. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid
16. Differential effects of nicotinic acid in subjects with different LDL subclass patterns
17. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a)
18. Familial hypercholesterolemia regression study: A randomised trial of low-density-lipoprotein apheresis
19. LDL-apheresis atherosclerosis regression study (LAARS)
20. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
21. Association of coronary atherosclerosis and hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (β) lipoproteins]
22. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Quebec cardiovascular study
23. Apo B and Lp(a): A clinician's perspective
24. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia
25. Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease
26. High-density lipoproteins and coronary atherosclerosis: A strong inverse relation with the largest particles is confined to normotriglyceridemic patients
27. A population at risk: Prevalence of high cholesterol levels in hypertensive patients in the Framingham study
28. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia
29. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
30. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol
31. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease
32. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer
33. Wine and your heart: A science advisory for healthcare professionals from the nutrition committee, council on epidemiology and prevention, and council on cardiovascular nursing of the American Heart Association
34. Plasma homocysteine levels and mortality in patients with coronary artery disease
35. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham study
36. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol
37. Apolipoprotein (B) identifies dyslipidemic phenotypes associated with cardiovascular risk in normocholesterolemic type 2 diabetic patients
38. Hyperinsulinemia as an independent risk factor for ischemic heart disease
39. Editorial: Interleukin-6: The endocrine cytokine
40. Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin-dependent diabetic patients: Influence of apolipoprotein E polymorphism
41. Relation of triglyceride metabolism and coronary artery disease: Studies in the postprandial state
42. Insulin-resistance, hypertriglyceridaemia and cardiovascular risk: The Paris prospective study
43. Fasting blood glucose: An underestimated risk factor for cardiovascular death
44. Effects of a traditional lifestyle on obesity in Pima Indians
45. Management of dyslipidemia in adults with diabetes
46. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
47. Cholesterol lowering with Simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
48. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects
49. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: A randomized trial
50. The Diabetes Atherosclerosis Intervention Study: Results
51. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)